RemeGen Co., Ltd.
HKSE: 9995.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jianmin Fang
- Employees
- 2,999
- Headquarters
- Yantai, China
- IPO year
- 2020
- Market cap
- HK$54.1B
- Website
- https://www.remegen.com
Loading 9995…
Loading profile data…Frequently asked questions about 9995
What does RemeGen Co., Ltd. (9995.HK) do?
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythemato...
Where does 9995.HK trade?
RemeGen Co., Ltd. (9995.HK) trades on the Hong Kong Stock Exchange.
What sector is 9995.HK in?
RemeGen Co., Ltd. (9995.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of RemeGen Co., Ltd.?
Jianmin Fang is the chief executive officer of RemeGen Co., Ltd. (9995.HK).
Where is RemeGen Co., Ltd. headquartered?
RemeGen Co., Ltd. is headquartered in China.
Does 9995.HK pay a dividend?
RemeGen Co., Ltd. (9995.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 9995.HK go public?
RemeGen Co., Ltd. (9995.HK) completed its initial public offering in 2020.